Abituzumab (DI17E6) is a humanised anti-integrin alphaV monoclonal antibody (IgG2 type). Abituzumab effectively reduces the phosphorylation of FAK, Akt and ERK. Abituzumab can be used in cancer research, particularly in prostate cancer[1].
Molecular Weight:
(144.58 kDa)
Purity:
99.38
CAS Number:
[1105038-73-0]
Target:
Integrin
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted
